The aim of the study was to assess the long-term eYcacy and safety of InXiximab therapy in the treatment of patients with Behçet's disease refractory to standard immunosuppressive agents. Twenty-one patients that did not respond to corticosteroids and to at least one immunosuppressant (cyclosporin, methotrexate, azathioprine, cyclophosphamide) for the presence of ocular and/or CNS involvement were enrolled. Eighteen patients completed the study up to 54 weeks. Stable doses of prednisone (<10 mg/day) were permitted, immunosuppressants were discontinued at least 4 weeks prior baseline visit. The patients received three infusions of 5 mg/kg InXiximab (at weeks 0, 2 and 6) and then infusions of 5 mg/kg InXiximab every 8 weeks. At each visit data on clinical symptoms, response to therapy and adverse events were collected. The primary outcome of interest was to assess the clinical eYcacy (total or partial recovery) of inXiximab. Secondary end points were to evaluate quality of life and to monitor the safety of the drug. Eighteen patients achieved a total remission. Two patients achieved a partial remission and relapsed after 3 months from discontinuation of therapy. InXiximab was well tolerated throughout the study. A case of non-Hodgkin lymphoma was observed within 6 months.
Introduction
Behçet's disease (BD) is a chronic inXammatory disorder aVecting various organ systems, characterized by recurrent oral aphthous ulcers, genital ulcers, uveitis, and skin lesions [1, 2] . All these common manifestations are self-limiting except for the ocular attacks. Repeated attacks of uveitis can cause blindness [1] [2] [3] . Involvement of the gastrointestinal tract, central nervous system, and large vessels is less frequent, although it can be life threatening [1, 2, [4] [5] [6] .
For most patients the treatment of BD is based on the combination of corticosteroids and immunosuppressive agents [7] . Despite the improvement obtained with this strategy, relapses and failure may occur. Some patients can also be refractory to all treatments.
The aetiology and pathogenesis of BD are unknown but there are considerable data indicating that immunological abnormalities are important. Several humoral and cellular abnormalities have been described, such as the high serum levels of IL-2, IFN-, TNF- [8] [9] [10] . These cytokines detected in patients with active disease point to a polarized Th1 immune response, as suggested by in vitro and in vivo studies of experimental autoimmune uveoretinitis [11] . We have also documented increased numbers of T lymphocytes expressing the gammadelta receptor that overproduce TNF in patients with active disease [12] and more recently a role of NF-kB in protecting T cells against CD95 induced apoptosis down-regulated by thalidomide, a TNF inhibiting agent [13] .
Case studies have indicated the eYcacy of inXiximab treatment of patients with BD in refractory ocular [14] [15] [16] , neurological [17, 18] , mucocutaneous [19] , and gastroenterological involvement [20, 21] .
This study was undertaken to assess the long-term eYcacy and safety of anti-tumor necrosis factor antibody inXiximab (Remicade; Centocor Inc, Malvern, PA; Schering Plough SpA, Italy) therapy in the treatment of patients with disease refractory to standard immunosuppressive agents.
Patients and methods

Patients
Eligible patients were 18 years of age or older, had active persistent BD diagnosed according to the international criteria for BD [22] , and a C-reactive protein concentration >1 mg/dl. Patient inclusion criteria were: failure to respond to corticosteroids and to at least one immunosuppressant (cyclosporin, methotrexate, azathioprine, cyclophosphamide) for the presence of ocular and/or CNS involvement. Major exclusion criteria consisted of prior use of TNF antagonist, a history of active infections or of an episode of major infection within 30 days prior to screening and any uncontrolled medical condition, pregnancy or breast-feeding.
Study protocol
The study was approved by the local ethics committee. All patients also gave their written informed consent. All patients had a normal chest-X-ray, a negative test for tuberculosis. Stable doses of prednisone (<10 mg/day) were permitted, immunosuppressants were discontinued at least 4 weeks prior baseline visit. The patients received three infusions of 5 mg/kg InXiximab (at weeks 0, 2 and 6) and then infusions of 5 mg/kg InXiximab, every 8 weeks for a total of 1 year.
Disease and safety assessment
At each visit data on clinical symptoms, response to therapy and adverse events were collected. Responses were deWned as: complete (C) when clinical signs of activity, as deWned by the BDCAF score [23, 24] , that includes the presence of several manifestations of the disease, by the uveitis scoring system and by the visual activity measurement [25] , were absent during the 12-month observation; partial (P) when the clinical response was incomplete; absent (A) when clinical manifestations remained stable.
Laboratory evaluation, including erythro-sedimentation rate (ESR), C-reactive protein (CRP), anti-nuclear antibodies and routinary hepatic and renal parameters and complete blood count, was also performed at baseline and before each infusion of InXiximab.
Results
The primary outcome of interest was to assess the clinical eYcacy (total or partial recovery) of inXiximab in patients with active disease for whom classical immunosuppressive therapy was insuYcient or inappropriate for all clinical manifestation of the disease. Secondary end points were to evaluate quality of life and to monitor the safety of the drug. The total duration of this study was 12 months. Patients who discontinued treatment due to lack of eYcacy were considered to be non-responders. Data for patients who discontinued study treatment for other reason (e.g., adverse events) were assessed for treatment response based on their observed values at the time of discontinuation. Twenty-one patients (18 males and 3 females, mean age 36 years, range 18-71) were enrolled into the study. Baseline demographic and clinical characteristics that include BDCAF scores and the result of therapy are shown in Table 1 . Organ involvement at presentation included cerebral vasculitis (n = 5), retinal vasculitis (n = 13) and posterior uveitis (n = 13). Other clinical manifestations were oral ulcers (n = 21), genital ulcers (n = 12), erythema nodosum (n = 7). Previous disease-related treatment included prednisone (n = 21), cyclosporine (n = 20), azathioprine (n = 8), cyclophosphamide (n = 2), chlorambucil (n = 1) methotrexate (n = 3), colchicine (n = 8) and interferon (n = 1). Eighteen patients completed the study up to 54 weeks. Eighteen patients achieved a total remission (Tables 1, 2) . Twelve of these patients decided to continue inXiximab treatment and remained free of symptoms. Six patients discontinued the treatment after 1 year observation and four of them relapsed after 3-6 months. InXiximab was able to control the other disease manifestations. Two patients achieved a partial remission and relapsed after 3 months from discontinuation of therapy. The remission was achieved at a mean time of 4.8 weeks. Three patients withdrew from the study, one for personal reason (at 37th week, responder), one during the 24th week of treatment because of a major adverse event (non-Hodgkin lymphoma, responder) and the last for lack of eYcacy (at 12th week). There were no recurrences after steroid tapering. No relationship was observed between the type of response to treatment and the duration of disease or the type of clinical presentation. In all patients, the treatments induced, also, a signiWcant and rapid reduction of laboratory inXammatory parameters (ESR and CRP; not shown). InXiximab was well tolerated throughout the study.
Minor side eVects were headache, dizziness, tachycardia that regressed spontaneously and did not entail interruption. Anti-nuclear antibodies were not detected during the period of observation.
Discussion
The primary goals of management of patients with BD are symptom control, early suppression of inXammation and prevention of end-organ damage, the treatment options being anti-inXammatory agents and immunosuppressants. Drugs are frequently used in combination in order to maximize eYcacy while minimizing side eVects and the spectrum of clinical manifestations requires close multidisciplinary co-operation for optimal care [26] .
Anti-TNF alpha agents have been successfully used in a number of inXammatory conditions other than rheumatoid arthritis, including Crohn's disease, ankylosing spondilytis, psoriasis, psoriatic arthritis and necrotizing vasculitis. The use of inXiximab in BD was Wrst described in 2001 [14] and since then a number of case series and single reports have been published. Initial indications for treatment were sightthreatening uveitis and severe inXammatory gastrointestinal disease. InXiximab has subsequently been used for severe orogenital ulceration and for cerebral vasculitis. These anedoctal case studies have generally reported an immediate and dramatic resolution of both organ-speciWc and systemic symptoms, often in patients refractory to conventional immunosuppression, and, to date, the number of randomized controlled trials in BD is increasing. DiVerences, however, exist in practical approaches to treatment and the long-term outcome is unknown. Indeed, BD is characterized, generally, by an intermittent course. In these conditions short course or single infusions seem to be suYcient to suppress disease activity for long periods. On the other hand, some patients have a chronic progressive course, recurrent posterior uveitis and retinal and cerebral vasculitis being considered of poor prognosis predictive value, and a sustained therapy is required. This study was designed to evaluate the long-term eYcacy and safety of anti-tumor necrosis factor antibody inXiximab therapy in the treatment of patients with BD refractory to standard immunosuppressive agents. The primary outcome of interest was to assess the induction of remission, which was achieved in more than 95% of the patients at a mean time of 4.3 weeks. Importantly, clinical remission was achieved in several patients with persistent disease activity despite dual or triple immunosuppressive therapies. No response was observed in just one patient. This patient was celiac, and it is not known whether this was the result of a failure of inXiximab to inhibit TNF mediated responses or a switch to other cytokine pathways as drivers of pathogenesis.
Anti-TNF withdrawn was followed by relapse in the two patients that achieved a partial remission indicating that in these patients a remission induction approach did not produce an optimal response in the medium/long term and after stopping therapy in some responders. Indeed, there have been several other case series providing the observation that patients frequently relapse after anti-TNF discontinuation.
Secondary end point was to monitor the safety of the drug. A patient developed a non-Hodgkin lymphoma. This condition is extremely rare in patients with BD [27] and probably related to anti-TNF therapy. In the other patients inXiximab was generally well tolerated during all the period of treatment.
A key target of biological therapy has been inhibition of the cytokine TNF , which has been implicated as a central proinXammatory messenger molecule in immunologically mediated diseases and as a critical cytokine in the physiopathology of BD.
The observation, in this and other studies (reviewed in Ref. [7] ), of the dramatic eVect of TNF inhibition on reduction of signs and symptoms of disease and on suppression, both in vivo and in vitro, of the number and the function of active lymphocytes implicated in the pathogenesis of BD [12] , induces to consider anti-TNF agents are truly superior to conventional immunosuppressive therapy. Additional randomized placebo-controlled long-term studies of inXiximab in BD are warranted, however, using larger patient groups. Furthermore, studies with planned anti-TNF discontinuation would have been much more interesting. 
